Bioxytran, Inc. (OTCPK: BIXT)
Health Care · Biotechnology · US
$0.02
+1.48% today · -72.3% 1Y
Bioxytran, Inc. (OTCPK: BIXT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.44M and employs 2 people.
Over the last twelve months the share price has lost 72.3%, trading between 0.02 and 0.09.
Tweenvest scores Bioxytran, Inc. across four factors: quality 5/100. Its strongest factor is quality.
BIXT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.44M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 1.97
- 52-week high
- $0.09
- 52-week low
- $0.02
- Avg volume (3M)
- —
- Shares outstanding
- 114.70M
- Employees
- 2
- Next earnings
- —
About Bioxytran, Inc.
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
- ISIN
- US09075D1028
- Founded
- 2008
- Listed since
- Jan 5, 2010
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.